L
Life Biosciences
Raised $80M in a Series D round, announced 8 April 2026.
Round
Life Biosciences closed an $80 million Series D financing to advance its programs.
- Amount
- $80M
- Stage
- Series D
- Announced
- 8 April 2026
- Use of funds
- Support operations into second half of 2027, completing Phase 1 trial of ER-100 and advancing PER platform.
- Checked
- Amount and date checked against the press source
Company
Life Biosciences develops therapies targeting age-related diseases through cellular reprogramming.
- Based in
- Boston, United States
- Sector
- Health
- Website
- lifebiosciences.com ↗
Founders
- David Sinclairco-founder
- Jerry McLaughlinChief Executive OfficerLinkedIn ↗
